On Tuesday, September 8, Pharvaris did something the HAE prophylaxis market had never seen: it ran a Phase 3 trial covering all three types of hereditary angioedema simultaneously and swept every endpoint. CHAPTER-3 is the first and only prophylaxis Phase 3 study to evaluate all three types of HAE, including people with HAE type 1, HAE type 2, and HAE with normal C1 inhibitor. The result was not marginal. The primary endpoint was met, with deucrictibant XR reducing the mean monthly HAE attack rate by 83% versus placebo across all three types of HAE, and by 87% in participants with HAE type 1 or type 2. Pharvaris also said no treatment-related serious adverse events were reported.
Pharvaris said data from the CHAPTER-3 study will serve as the basis for marketing authorization applications, planned to be submitted starting in the first half of 2027. That filing timeline is not distant. It is less than nine months away, and the market moved accordingly.
The Story Behind the Trade
The incumbents that stand to lose the most are Takeda (TAK) and BioCryst (BCRX). Takeda’s injectable lanadelumab, sold as Takhzyro, is the dominant prophylaxis product in the space. Takeda reported Takhzyro sales of JPY 59.9 billion in the first quarter of its fiscal year ending March 31, 2027 (April 1 to June 30, 2026), and said the increase was partially offset by a sales decline in the U.S. due to increased competition. That competition just got materially louder.
BioCryst felt Tuesday’s data immediately. Shares of BioCryst fell sharply on Tuesday, clocking their worst day since late February with a 9% decline. Investors marked down Orladeyo on the risk of a stronger oral rival after 2027. Orladeyo sales have continued to grow, and the company is guiding for $625 million to $645 million in 2026 revenue from the drug. That guidance now carries a shadow.
BioCryst is not defenceless. Patient enrollment in the pivotal ALPHA-ORBIT trial for navenibart was completed in June, and BioCryst has said it expects to report top-line data in the third quarter of 2027. Management has positioned navenibart as a hedge against oral competition. That story is real, but it depends on data that will not arrive for another year. Between now and then, Pharvaris controls the headlines.
Technical and Fundamental Alignment
Both TAK and BCRX sold off on September 8 but did not crater. That gap between a meaningful competitive threat and a measured market reaction is where options pricing becomes interesting. BCRX already traded at a discount to sector peers before this week. Analysts have flagged pressure on projected profit margins and increased reliance on navenibart’s success, but the specific fair value-change figures vary by firm and are not consistently reported. A stock under fundamental pressure with a known overhang and a 12-plus month catalyst vacuum is a candidate for continued drift lower.
Options Perspective
The structure that fits here is a put debit spread on BCRX. After the initial 9% drop, implied volatility has likely risen, which makes outright long puts expensive. A spread defines the cost, captures downside exposure into the 2027 filing window, and limits the damage if navenibart data or M&A speculation sparks a relief rally. Targeting expiration in March or April 2027 keeps the position alive through the Pharvaris NDA filing period while avoiding unlimited premium bleed.
For TAK, the calculus differs. Takhzyro is one product inside a company that generated about JPY 4.6 trillion in revenue in the fiscal year ended March 31, 2026. The stock will not move the way BCRX moves. But TAK’s relative weakness against broad pharma since the CHAPTER-3 announcement creates a tactical opportunity for a short-duration bear put spread positioned around the next earnings catalyst, where analysts will press management on the Takhzyro competitive outlook directly.
Risk Management
Two events could unwind this thesis quickly. First, navenibart delivering early efficacy signals ahead of schedule would shift sentiment hard into BCRX. Second, Pharvaris facing a regulatory surprise, a request for additional data or a delayed filing, would remove the competitive pressure and likely spark a relief rally in both incumbents. Position sizing matters here. Neither spread should represent more than 2% to 3% of portfolio risk, and both carry defined maximum loss equal to the net premium paid.
The Beast Verdict
Pharvaris ran a cleaner Phase 3 trial than anyone had built into consensus. The company said the primary endpoint and all secondary efficacy endpoints were met with statistical significance. That result is not a probability anymore. It is a fact the HAE market has to absorb. The incumbents had nine months of runway before a filing arrives. Options on BCRX and TAK price that runway cheaply right now. A bear put spread on BCRX, expiring in early 2027, is the highest-conviction expression of this thesis with risk contained from the first trade.
